HOME

TheInfoList



OR:

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as
huC242 Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen. It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates : * Cantuzumab mertansine * ...
it binds the
CanAg Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen. It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates : * Cantuzumab mertansine * ...
antigen. It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates : *
Cantuzumab mertansine Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM ...
*
Cantuzumab ravtansine Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody ''cantuzumab'' (huC242) is linked to a cytotoxic agent, ravtansine (DM4). It uses a more hindered disulf ...


huC242 targets CanAg

"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of
MUC1 Mucin short variant S1, also called polymorphic epithelial mucin (PEM) or epithelial membrane antigen (EMA), is a mucin encoded by the ''MUC1'' gene in humans. Mucin short variant S1 is a glycoprotein with extensive O-linked glycosylation of its e ...
). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)."A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
/ref>


References

Monoclonal antibodies {{monoclonal-antibody-stub